All smiles as SDI reports profit jump
28 February, 2002 by Tanya HollisDental research group SDI has reported a half-yearly jump in profits and sales on the back of its suite of aesthetic and alloy restorative products.
Australian researchers wasting IP, warns patent expert
28 February, 2002 by Tanya HollisAustralian researchers were wasting 90 per cent of their intellectual property value because they did not understand how to use it, a patent attorney has warned.
WA biotech mines double benefit from listing vehicle
27 February, 2002 by Pete YoungBacking hopeful young companies into the listed shells of mining companies is an old habit in Western Australia.
Australian biotechs must merge or perish: Ernst and Young
27 February, 2002 by Tanya HollisAustralia's biotechnology companies will have to merge or perish, according to leading industry analyst Ernst and Young.
Xenome chief flags industry insurance fears
27 February, 2002 by Pete YoungThere are fears the current insurance industry upheaval will force some biotechs to the wall unless the Gene Technology Act 2000 is overhauled.
CSIRO lifting its game: Garrett
26 February, 2002 by Tanya HollisCSIRO was well on its way to addressing the raft of serious problems outlined in a confidential internal report, the organisation's chief has claimed.
Cone snail proving to be companies' best friend
26 February, 2002 by Melissa TrudingerThe cone snail, a marine snail from the Great Barrier Reef, is proving to be a vaulable ally in pain management drug research.
Consolidation contributes to Agenix half-year profit
26 February, 2002 by Daniella GoldbergAgenix Limited (ASX: AGH) has announced a 435 per cent increase in after-tax profit to $1.7 million for the six months to December 31, 2001.
Go west, young biotech entrepreneur
25 February, 2002 by Daniella GoldbergBioWest, the first directory for the biotechnology industry in western Sydney, is being launched today by Kim Yeadon, NSW Minister for Western Sydney.
Thrombogenix to change its name
22 February, 2002 by Tanya HollisKinase and blood-clotting disease research group Thrombogenix is within weeks of a name change intended to reflect a broader focus.
We'll float when we're ready, says PSL chief
22 February, 2002 by Daniella GoldbergSydney-based company Proteome Systems Limited (PSL) has participated in a new round of capital raising as speculation mounts about the timing of the company's public float.
'Poor performer' biotechs urge shareholders to take the long view
22 February, 2002 by Pete YoungTwo biotech companies, Biota Holdings and Progen Industries, have popped up on the Australian Shareholders Association's 2002 list of 'Poor Performers'.
Growth for GroPep in Biotech Australia buy
21 February, 2002 by Tanya HollisCell growth factor company GroPep is expecting to record a profit within six months after finalising its purchase of Biotech Australia Group.
Queensland biotech's reclusive benefactor
21 February, 2002 by Pete YoungSelf-made billionaire and secretive philanthropist Charles Feeney appears to have a soft spot for Queensland's biotechnology sector.
Ciphergen teams up on AIDS research using protein chips
20 February, 2002 by John DodgeUS company Ciphergen Biosystems has signed two joint development agreements that will call on its protein chips to find out why AIDS does not progress in a small percentage of HIV-infected individuals.
